Introduction
The DNA mismatch repair (MMR) system, responsible for the recognition and repair of single base mispairs, small insertions and deletions, which result from replication errors or physical/chemical damage to DNA, and the prevention of homeologous recombination, was initially described in E. coli (reviewed in references Kolodner, 1995; Modrich and Lahue, 1996) . In bacteria, initial recognition of mismatches arising during DNA replication is carried out by the MutS protein, which in turn recruits MutL and then MutH, the latter nicking the DNA at the nearest hemimethylated GATC site. The nascent strand is excised by exonuclease activity which is followed by patch repair (reviewed in Kolodner, 1995; Marra and Schar, 1999) . Eukaryotes have a system similar to that of bacteria, and a number of MutS and MutL orthologs have been identi®ed in both yeast and mammals. The orthologs of MutS, MSH2, MSH6, and MSH3 participate in primary recognition, with MSH2 functioning as an obligate partner in two heterodimers: MutSa, composed of MSH2 and MSH6, primarily binds to single base loop and base/base mispairs; and MutSb, made up of MSH2 and MSH3, recognizes insertion/deletion loops (IDLs) (reviewed in Jiricny, 1998; Kolodner and Marsischky, 1999; Marra and Schar, 1999) . Yeast MutLa, which appears to be involved in the repair of both mismatches and IDLs, is a MLH1 and PMS1 heterodimer, whereas mammalian MutLa is composed of MLH1 and PMS2 (PMS2 being the closest mammalian ortholog to yeast PMS1) (Guerrette et al., 1999; Jiricny, 1998; Kolodner and Marsischky, 1999; Marra and Schar, 1999; Prolla et al., 1994) . In yeast a second complex containing MLH1 and MLH3 (MLH3 being the closest ortholog of mammalian PMS1), MutLb, also participates in the repair of a subset of frameshift errors (Flores-Rozas and Kolodner, 1998) . In humans, the presence of an hMLH1/ hPMS1-containing MutLb complex has recently been demonstrated (Raschle et al., 1999) , but no biochemical function has been ascribed to this heterodimer thus far.
Mutations in one of ®ve dierent mismatch repair genes, primarily hMSH2 and hMLH1, and to a lesser extent hPMS2, hPMS1 and hMSH6, account for most cases of the autosomal dominant familial cancer syndrome, hereditary nonpolyposis colorectal cancer (HNPCC) (Kolodner, 1995; Prolla, 1998; Toft and Arends, 1998; Wang et al., 1999b) . In most instances aected individuals inherit a germline mutation on one allele and associated with a loss of heterozygosity develop predominantly colon, endometrial, and ovarian tumors, as well as malignancies of the stomach, pancreas, small intestine, skin, breast and urinary tract (Prolla, 1998; Toft and Arends, 1998; Wang et al., 1999b) . Homozygous germline inactivation of a MMR gene was reported recently in two families. In both cases, hMLH1-de®cient children developed hematological malignancies and neuro®bromatosis type 1-like features at an early age (Ricciardone et al., 1990; Wang et al., 1999a) . MMR genes can also be functionally inactivated via transcriptional silencing, as shown for hMLH1 in various human cancers (Herman et al., 1998; Leung et al., 1999; Simpkins et al., 1999; Wheeler et al., 1999) .
Mouse models of MMR de®ciency have been developed via gene targeting, thus enabling study of the roles of various MMR genes in mutagenesis and carcinogenesis (reviewed in Heyer et al., 1999) . Mice with homozygous de®ciencies in the MutL orthologs Mlh1 and Pms2 generally exhibit similar increases in genome instability and both are prone to malignancy, with lymphomas being the predominant tumor type (Baker et al., 1995 (Baker et al., , 1996 Narayanan et al., 1997; Prolla et al., 1998) . In contrast, an increased predisposition to malignancy has not been evident in Pms1 7/7 mice . Interestingly, while Mlh1 7/7 mice develop small intestinal tumors, consisting of both adenomas and adenocarcinomas, Pms2 7/7 mice do not develop tumors at this site. The discordant tumor spectrum of the Mlh1
and Pms2
7/7
mice has suggested a dierential role for these two proteins in tumor formation, likely as a result of dierences in genomic instability. In keeping with this, Yao et al. (1999) recently demonstrated that mice de®cient in Mlh1 exhibited a greater degree of instability at repetitive sequences than did mice lacking Pms2.
To enable a quantitative and qualitative assessment of mutations in the mice de®cient for the two components of MutLa, Mlh1 +/7 mice and Pms2
mice were crossed with the BC-1 line (Andrew et al., 1996) which carries a transgenic lacI mutational reporter gene, to obtain Mlh1
/lacI + and Pms2 7/7 / lacI + mice. lacI mutant frequencies (MF) and mutation spectra were determined for puri®ed small intestinal epithelial cell DNA, a site showing dierential susceptibility to cancer in Mlh1 7/7 and Pms2 7/7 mice. Thus, Mlh1 7/7 mice showed a 1.5-fold increase in MF as compared to Pms2 7/7 hosts. Sequence analysis of the lacI mutants revealed that this dierence was primarily due to an *twofold increase in C : G?T : A changes in the Mlh1 7/7 mouse small intestinal DNA. This increase in point mutations may in part account for the discordance with respect to small intestinal neoplasia in these mice. Furthermore, the results provide additional evidence for dierential roles of MLH1 and PMS2 in the mammalian MMR process. 7/7 and Pms2 7/7 mice was unlikely to be the result of variations in genetic background. Furthermore, as the mice analysed were of a similar ages (1 ± 2 month old, see Table 1 ), it indicated that the Mlh1; Pms2 genotypes were responsible for the observed MF dierences in these two knockout lines.
Results

Mutant
Mutational spectra
The mutational spectra of MMR-de®cient small intestinal epithelial cells was determined by sequencing of 12 ± 15 lacI mutants per mouse. In total, 74 Mlh1
and 71 Pms2 7/7 lacI mutants were characterized (Table  2) . To guard against the possibility that recurrent lacI mutants may have been clonal in origin, mutations seen more than once in the same animal were eliminated from the analysis. The resultant corrected mutational spectra is shown in Table 2 . It should be noted that recurrent lacI mutations may be due to independent mutations occurring at DNA`hotspots'. Thus, for example, a 71 deletion of an A at positions 135 ± 139 was seen in nine of the 10 mice, G? A transitions at positions 56 and 180 were each seen in four mice, and C?T transitions at position 42 of the lacI gene were seen in four dierent mice. Nevertheless, as the percentage of recurrent mutations was relatively low, being 12% in the Mlh1 7/7 and 17% in the Pms2 7/7 mice, the mutational spectra were not greatly altered following correction for clonality.
Base transitions predominated in lacI mutants isolated from Mlh1 7/7 and Pms2 7/7 mice, followed by insertion/deletion mutations, and transversions (Table 2) . However, when the numbers of lacI mutants within these various categories are compared, a signi®cant dierence between Mlh1 7/7 and Pms2
small intestinal cells was evident (w 2 test, P50.05 for both the original spectra and after correction for clonality). In order to ®nd the type of mutation responsible for this dierence, the distribution of Mlh1 7/7 and Pms2 7/7 mutations as a percentage of the total number was compared. As shown in Table 2 , base transitions accounted for 63% of the Mlh1 7/7 and 44% of the Pms2 7/7 intestinal lacI mutations. Within the transitions, interestingly, C : G?T : A mutations predominated over T : A?C : G changes. Amongst C : G?T : A transitions, mutations were seen at CpG animals. Deletions/insertions were represented by frameshifts of 1, 2, or 4 nucleotides, with deletions predominating (480%) in both knockout lines. More than 90% of the changes were single nucleotide deletions within mononucleotide repeats of 3 ± 5 nucleotides (data not shown) and these occurred in both the Mlh1 7/7 and Pms2
mice. The number of expansions were uniformly low in all the MMR de®cient mice, and there was no signi®cant dierence between the contraction and expansion mutations in the two lines (w 2 test, P40.05).
Although the percentage of deletion/insertion mutations was higher in the Pms2 7/7 than in the Mlh1 7/7 animals (being 37% and 23%, respectively), a simple comparison of percentages may not be the best way to compare the mutational spectrum of the mice owing to the ®nding that the lacI mutant frequency was *1.5-fold higher in Mlh1 7/7 than in Pms2 7/7 mice. Thus, for every 100 lacI mutations in Pms2 7/7 mice there would be approximately 150 lacI mutations in Mlh1
mice. To allow a more accurate comparison between the absolute numbers of the types of mutations, the hypothetical distributions of 150 Mlh1 7/7 and 100 Pms2 7/7 lacI mutations were calculated based on the spectra of independent mutations (obtained from Table  2 ). These are presented in Figure 2 . It was evident that the major dierence between Mlh1 7/7 and Pms2 7/7 mice was in the C : G?T : A transition mutations whose numbers more than doubled in the Mlh1 and Pms2 7/7 mice, respectively, did not change as animals is primarily the result of an elevated number of C : G?T : A transitions.
Discussion
The mammalian MLH1 and PMS2 proteins participate in the mismatch repair pathway as a heterodimer. However, MLH1 and PMS2 de®cient mice show a dierent phenotype regarding their tumor spectrum, speci®cally, in their predisposition to malignancies of the small intestine . To determine whether this might be a consequence of the dierential role of the two proteins in DNA MMR, we assessed mutant frequencies and mutational spectra within the small intestinal epithelial cell DNA obtained from Mlh1 7/7 and Pms2 7/7 mice employing a lacI transgenic forward mutation detection system. The lacI gene can be inactivated by a wide range of mutations, including a great variety of transitions, transversions and frameshifts, and to date, more than 600 sites of inactivating mutations have been described (de Boer and Glickman, 1998) . Using this system to assess lacI mutations in Mlh1 7/7 and Pms2 7/7 small intestinal cells, we have shown that although MLH1/PMS2 may both be required for the repair of base substitutions and insertions/deletions, MLH1 may be involved in a PMS2-independent repair pathway particularly involving DNA lesions that result in C : G?T : A transition mutations.
Recently, a study of microsatellite instabilities and frameshift mutations in mono-and dinucleotide repeats was carried out in Mlh1 7/7 and Pms2 7/7 mice (Yao et al., 1999) . This study revealed a signi®cant dierence between the expansion and contraction mutations within these repeats, which resulted in elevated frameshift mutant frequencies in Mlh1 7/7 mice (Yao et al., 1999) . With the lacI reporter system, however, we did not ®nd a similar dierence in expansions and contractions. Although dierent tissues were assessed in these two studies (colon and skin versus small intestinal epithelial cells in this study), the observed dierence is more likely a re¯ection of the mutational assay system employed. Mutant frequencies and mutation spectra depend not only on the speci®c reporter genes employed, but also such variables as sequence context, DNA methylation, chromosomal location and transcriptional activity (Dogliotti, 1996) . The lacI gene, for example, lacks long mononucleotide repeats such as those present within the supF reporter gene or microsatellite sequences used by Yao et al. (1999) . Indeed, as lacI gene mononucleotide repeats are generally 56 nucleotides in length, it is possible that dierences in the ratio of expansions-to-contractions in Mlh1 7/7 and Pms2 7/7 mice are not possible to observe with the lacI reporter system. On the other hand, the supF reporter gene employed by Yao et al. (1999) is not ecient for assessing single base substitutions, which are more readily accessible using the lacI system. Figure 2 Predicted distributions of the mutational spectra of 150 Mlh1 7/7 and 100 Pms2 7/7 lacI mutants obtained from small intestinal epithelial cell DNA (calculation was based on the spectra of independent mutations shown in Table 2) Increased mutations in Mlh1 7/7 vs Pms2 7/7 mice A Baross-Francis et al Thus using two dierent reporter gene systems it is possible to obtain a more complete picture of the mutational consequences of MLH1 and PMS2 de®-ciency. Interestingly, and consistent with our ®ndings, the spectra of mutations in hMlh1 and hPms2 de®cient human tumor cell lines using hypoxanthine-guanine phosphoribosyltransferase (hprt) as the reporter, demonstrated a reduction in C : G?T : A transitions in cells lacking hPMS2, relative to the hMLH1 de®cient cells (Kato et al., 1998) . The major causes of C : G?T : A transitions in mammals include the generation of G : T (or C : A) mismatches during DNA replication, recombination events, or deamination of 5-methylC at CpG sites (reviewed by Marra and Schar, 1999) . Non-methylated cytosines can also undergo deamination to uracil, which can potentially lead to C : G?T : A changes. In Mlh1 7/7 mice, for example, C : G?T : A transitions were increased at non-CpG (over CpG) sites (Table 2) , suggesting an impaired recognition/repair of G : T mismatches arising as a result of DNA polymerase errors, rather than from deaminations of methylC residues. Thus, as MMR proteins are thought to follow the DNA polymerase replication complexes (reviewed by Jiricny, 1998; Kolodner and Marsischky, 1999) , we speculate that MLH1 and PMS2 proteins may have dierential roles in the repair of G : T or C : A mismatches arising as a consequence of DNA polymerase-induced misincorporations. However, as C : G?T : A transitions were also increased, albeit to a lesser extent, at CpG sites in Mlh1 7/7 mice, a dierence in the roles of MLH1 and PMS2 in the repair of G : T or C : A mispairs arising from the various mutagenic sources mentioned above is possible.
The dierences between Mlh1 7/7 and Pms2 7/7 mice with respect to mutant frequencies and mutation spectra suggests that MLH1 might associate with other MutL orthologs, such as PMS1 or MLH3, during MMR. It was recently shown, for example, that hMLH1 dimerizes with hPMS1 to yield the complex hMutLb (Raschle et al., 1999) . Although a speci®c biochemical function for hMutLb has not yet been demonstrated in vitro (Raschle et al., 1999) , it remains possible that this complex participates in some aspect of MMR in vivo. This is consistent with the ®nding of a hPMS1 mutation in an HNPCC kindred, which raises the possibility that hPMS1 does play an important role in the maintenance of genome stability (Prolla, 1998; Toft and Arends, 1998; Wang et al., 1999b ). An additional mammalian MutL ortholog, MLH3, was recently cloned from humans and mice (Lipkin et al., 2000) . Sequence alignments show that hMLH3 is more closely related to yeast MLH3 than is hPMS1. hMLH3 was shown to interact with hMLH1, and cells transfected with a dominant negative mutant of hMLH3 protein exhibited microsatellite instability (Lipkin et al., 2000) . We hypothesize that MLH1 : PMS2 (MutLa) associates with both MutSa and MutSb during MMR, and it is possible that MLH1 : PMS1 (MutLb) and/or the MLH1/MLH3 complexes may similarly be capable of interacting with MutSa. Our results suggest that either one or both of the latter two MutL complexes might be involved in the repair of some fraction of the DNA lesions that are manifested by the excess of C : G?T : A transitions in Mlh1 7/7 mice (as compared to Pms2 7/7 mice). Yeast MLH3, which forms a functional heterodimer with MLH1, has been shown to play a role in the repair of frameshifts (Flores-Rozas and Kolodner, 1998) . While this complex may also have a role in the repair of mismatches, it is possible that the yeast and mammalian MutL homologs will dier with respect to their ®ne speci®cities, similar to the dierences seen when MutS and MutL homologs in E. coli and S. cerevisiae are compared . It would be of interest to assess lacI gene mutations in mice with combined de®ciencies of Pms2 and Pms1, or Pms2 and Mlh3. This might shed light on which complex is primarily responsible for the correction of G : T mispairs that arise in Pms2 7/7 small intestinal cells. It would also be of interest to determine whether either of these double mutants develop intestinal tumors with a frequency similar to that of Mlh1 7/7 mice. While the elevation of C : G?T : A transitions in Mlh1 7/7 mice is unlikely to fully explain the tendency of Mlh1 7/7 mice to develop small intestinal tumors, it may well be a contributing factor in this process through the inactivation of tumor suppressors or the activation of proto-oncogenes. Interestingly, a high increase of frameshifts does not seem to be critical to tumorigenesis in MMR de®cient hosts, since older Msh6 7/7 mice still appear to be prone to intestinal tumors despite lacking the high levels of microsatellite instability seen in Mlh1 7/7 mice (Edelmann et al., 1997) . For example, a candidate for inactivation via C : G?T : A transition mutations is the adenomatous polyposis coli (Apc) gene, which frequently undergoes loss-of-function mutations in colorectal cancer . Apc has been shown to be inactivated by C : G?T : A transitions (Huang et al., 1996; Lazar et al., 1994; Olschwang et al., 1997) . The p53 and K-ras genes are also often mutated in intestinal cancer, with many of the key pro-oncogenic changes in these genes resulting from C : G?T : A mutations (Lazar et al., 1994; Olschwang et al., 1997) . Loss of the tumor suppressor gene PTEN, has also been associated with intestinal tumor formation in PTEN +/7 mice (Di Cristofano et al., 1998; Suzuki et al., 1998) , and PTEN in human tumors can be inactivated by various C : G?T : A transitions (Lynch et al., 1997) . These selected examples highlight some of the key growth control genes that might represent targets for the increased level of transition mutations that we see in Mlh1 7/7 intestinal DNA.
Materials and methods
Transgenic mice
Mlh1 +/7 and Pms2 +/7 mice (C57BL/6) were crossed with the BC-1 lacI transgenic line (BALB/c) (Andrew et al., 1996) , Oncogene Increased mutations in Mlh1 7/7 vs Pms2 7/7 mice A Baross-Francis et al thus the resulting mice are of a mixed C57BL/6 and BALB/c background. Hemizygous BC-1 carry *30 copies of a lphage shuttle vector transgene containing the lacI reporter gene. Mlh1 or Pms2 heterozygous lacI + mice were bred to obtain knockout lacI + animals. For genotyping, 0.5 cm tail clips, obtained from anesthetized mice, were digested in 1.2 mg/ml proteinase K, 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 0.1% SDS, and 100 mM NaCl. Following heatinactivation of the proteinase, 1 ml of a 20-fold dilution was used in PCR reactions to determine the Mlh1 (Baker et al., 1996) , Pms2 (Baker et al., 1995) and lacI genotypes (Andrew et al., 1996) . Mice between the ages of 1 ± 2 months were sacri®ced by carbon-dioxide inhalation. Mice were viral antibody-free and housed in a barrier facility according to institutional guidelines.
Isolation of small intestinal epithelial cells
The middle one-third (*15 cm) of the small intestine of each mouse was¯ushed out with sterile phosphate-buered saline, then inverted using a probe to enable intestinal epithelial cell isolation as described (The Big Blue Website). The epithelial cells were suspended in 3 ml of sterile buer containing 75 mM KCl and 20 mM EDTA, and then¯ash-frozen in liquid nitrogen prior to DNA isolation.
Determination of lacI gene mutant frequency and mutation spectrum
Isolation of tissues and transgenic l-phage rescue were carried out as described (Kohler et al., 1990 (Kohler et al., , 1991 . Phage genomes were excised from chromosomal DNA and packaged using Transpack (Stratagene) phage packaging extract. Rescued phage were then plated on SCS-8 (Stratagene) bacterial lawns containing X-gal, and lacI mutant frequencies obtained by determining the ratio of mutant (blue) to nonmutant (colorless) plaques. At least 200 000 plaque forming units (pfu) were plated from each tissue sample. Phage containing lacI mutations were con®rmed by replating as previously described (Andrew et al., 1996) . Following isolation of mutant clones, lacI genes were ampli®ed by PCR and puri®ed using QIAquick DNA puri®cation kit (Qiagen). Templates obtained from randomly selected lacI mutants were sequenced using primers that spanned the lacI gene (Andrew et al., 1996) with an ABI 388 DNA sequencing instrument (Applied Biosystems).
